All Publications

Export 174 results:
Author Title Type [ Year(Asc)]
2017
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams D, Hamzah L, Sabin C and Post F. AIDS, 2017 Feb 20, Volume 31, Issue 4, p.485-492, (2017)
REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. Howarth A, Apea V, Michie S, Morris S, Sachikonye M, Mercer C, Evans A, Delpech V, Sabin C and Burns F. Health Services and Delivery Research, Volume 5, Issue 13, (2017)
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, Monforte A, Mary-Krause M, Roca B, Miro J et al. HIV Med, 2017 Jan, Volume 18, Issue 1, p.33-44, (2017)
A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell A, Cooper C, Hill T et al. HIV Med, 2017 Apr 24, (2017)
A time-updated continuum of care in a UK cohort Howarth A, Hill T, Burns F, Sabin C, Jose S and Delpech V. 23nd Annual Conference of the British HIV Association (BHIVA), Volume HIV Medicine, 18 (Suppl. S1), 3–13, p.Oral O15, (2017)
2016
Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Martin N, Thornton A, Hickman M, Sabin C, Nelson M, Cooke G, Martin T, Delpech V, Ruf M, Price H et al. Clin Infect Dis, 2016 May 01, Volume 62, Issue 9, p.1072-1080, (2016)
Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Booth J, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar E, Turner-Stokes T, Khatib N, Das P et al. Nephrol Dial Transplant, 2016 Dec, Volume 31, Issue 12, p.2099-2107, (2016)
Efaviranz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. HIV-CAUSAL Collaboration. Cain L, Caniglia E, Phillips A, Olsen A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I et al. Medicine (Baltimore), Volume Oct;95(41):e5133, (2016)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. The TenoRes Study Group . Lancet Infect Dis, Volume 16, p.565-575, (2016)
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre J, Amieva H, Cabié A, Williams I, Di Perri G, Tellez M et al. HIV Med, 2016 Jun, Volume 17, Issue 6, p.471-8, (2016)
Impact of transmitted thymidine analogue mutations on responses to first-line ART Geretti A, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Sabin C, Dunn D and for the HIV Drug Resistance Database and CHIC Study. CROI 2016, Volume Top Antivir Med. 2016; 24(e-1):189, p.Abstract 482 Poster, (2016)
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro M, Günthard H, Wittkop L, Kordossis T, García F et al. J Antimicrob Chemother, 2016 May, Volume 71, Issue 5, p.1352-60, (2016)
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams D, Hamzah L, Sabin C and Post F. International Congress of Drug Therapy in HIV Infection 2016, Volume J Int AIDS Soc 2016, 19 (Suppl 7), p.P218 Poster, (2016)
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. . AIDS, 2016 Jan 28, Volume 30, Issue 3, p.503-13, (2016)
No effect of HIV-1 subtype C on virological failure rate with first-line TDF regimens. White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn D and for the HIV Drug Resistance Database and the UK Collaborative HIV Cohort. CROI 2016, Volume Top Antivir Med. 2016; 24(e-1):190, p.Abstract 484 Poster, (2016)
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom. White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D and Dunn D. J Infect Dis, 2016 Nov 01, Volume 214, Issue 9, p.1302-1308, (2016)
Patients with perinatal HIV transitioning to adulthood in the UK: clinical outcomes in adult care. Collins J, Parrott F, Sabin C, Hill T, Jose S, Judd A and on behalf of the Collaborative HIV Paediatric Study(CHIPS) Steering Committee and the UK Collaborative HIV Cohort Study(CHIC). 8th International Workshop on HIV Pediatrics, 2016, Volume Reviews in Antiretroviral Therapy & Infectious Diseases 2016_7 , p.Abstract P_82, (2016)
Patients with perinatal HIV transitioning to adulthood in the UK: clinical outcomes in adult care. Parrott F, Sabin C, Collins J, Hill T, Jose S and Judd A. 2nd Adolescent Transition Workshop 2016, p.Oral, (2016)
Predicting virological decay in patients starting combination antiretroviral therapy. . AIDS, 2016 Jul 17, Volume 30, Issue 11, p.1817-27, (2016)
Quality of cause-of-death reporting in an on-going UK cohort study Jose S, Hill T, Pett S, Sabin C, Post F, Arenas-Pinto A, Delpech V and Croxford S. 22nd Annual Conference of the British HIV Association (BHIVA), 2016, Volume HIV Med 2016; 17 Suppl. 1. p14-71., p.Poster P126, (2016)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. Jose S, Quinn K, Dunn D, Cox A, Sabin C and Fidler S. HIV Med, 2016 May, Volume 17, Issue 5, p.368-72, (2016)
2015
Age, gender, risk group, cohort size and year of study effect on the performance indicator of CD4 count at HIV presentation: a UK CHIC study on late diagnosis performance. Gompels M, Michael S, May M, Jose S, Sabin C and on behalf of UK CHIC. 15th European AIDS Clinical Society 2015, p.Poster BPD2/4, (2015)
Development of a new measure to characterise retention in outpatient HIV care Howarth A, Burns F, Jose S, Hill T, Sabin C and Apea V. 21st Annual Conference of the British HIV Association (BHIVA), 2015, Volume HIV Medicine 2015; 16 (Suppl. 2), 12–77, p.Poster 171, (2015)
Hepatitis B treatment strategies and virological outcomes in the UK Collaborative HIV Cohort (UK CHIC) study Thornton A, Sabin C, Jose S, Rodger A, Dunn D, Gilson R, Bhagani S, Chadwick D, Fisher M, Main J et al. 21st Annual Conference of the British HIV Association (BHIVA), 2015, Volume HIV Medicine 2015; 16 (Suppl. 2), 12–77, p.Poster 65, (2015)
Initiation of anti-retrovirals in HIV/HCV-coinfected MSM: Are we too late? Martin T, Nelson M, Jose S, Thornton A, Sabin C, Martin N and Hickman M. 21st Annual Conference of the British HIV Association (BHIVA), 2015, Volume HIV Medicine 2015; 16 (Suppl. 2), 1-11., p.Oral 22, (2015)